Accendra Health Q2 profit, revenue miss estimates on large payor exit

Accendra Health

10/08/2026 11:53

Overview
US home healthcare firm's Q2 revenue fell and missed analyst expectations
Adjusted loss per share and adjusted EBITDA for Q2 both missed analyst expectations
Company reduced total debt by $385 mln
Company says CEO Ed Pesicka to retire by end-2026

Outlook
Accendra Health sees 2026 revenue at $2.45 bln to $2.55 bln
Company expects 2026 adjusted EBITDA of $300 mln to $320 mln
Accendra Health expects 2026 free cash flow to be breakeven to slightly positive

Result Drivers
COMMERCIAL PAYOR EXIT - Co said exit of large commercial payor reduced annualized operating expenses but contributed to lower revenue
EXPENSE RATIONALIZATION - Co cited increased emphasis on expense rationalization as part of ongoing restructuring
GROWTH INITIATIVES - Co said progress on new strategic partnerships and rollout of Sleep Center of Excellence expected to drive topline and bottom line expansion opportunities in late 2026 and 2027

Company press release: ID:nBwc65RSha

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$613.20 mln
$627.31 mln (6 Analysts)
Q2 Adjusted Loss Per Share
Miss
$0.19
$0.09 (6 Analysts)
Q2 Net Loss
 
$89.07 mln
 
Q2 Adjusted EBITDA
Miss
$60.10 mln
$61.32 mln (6 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Accendra Health Inc is $4.50, about 60.7% above its August 7 closing price of $2.80
The stock recently traded at 5 times the next 12-month earnings vs. a P/E of 5 three months ago

Reuters Recommended Reads
Aug 7 - National Healthcare Q2 revenue rises 8.8% on acquisitions
Aug 9 - RadNet raises outlook as Q2 revenue jumps 25%, adjusted EPS beats estimates 
Aug 7 - ResMed shares tumble as weak 2027 sales forecast eclipses quarterly profit beat

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)